Medmonitor

A first-in-class medication, this drug is indicated to delay the onset of Stage 3 type 1 diabetes, potentially delaying the clinical diagnosis of type 1 diabetes to provide patients with months to years without the burdens of disease.

Indicated to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations

Indicated for the topical treatment of plaque psoriasis of up to 20% body surface area involvement

Indicated for the treatment of hypertension, to lower blood pressure

Indicated for the treatment of HIV-1 infection

Indicated for the treatment of moderate-to-severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Indicated for the adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD)

Indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome

For the treatment of major depressive disorder, this antidepressant is notable for producing antidepressant results within one week

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Indicated for the treatment of hypertension to lower blood pressure

An NSAID used for the relief of mild to moderate pain or relief in the signs and symptoms of rheumatoid arthritis or osteoarthritis

Indicated for topical treatment of plaque psoriasis

Indicated as an adjunctive therapy for the treatment of partial-onset seizures, this approval is for the first liquid formulation of zonisamide.

Indicated for the treatment of partial-onset seizures.

A biosimilar to Rituxan^® with existing oncology indications, this drug is now approved for the treatment of moderate-to-severe rheumatoid arthritis, in combination with methotrexate.

Approved for its third indication for moderately to severely active Crohn’s disease, in addition to existing indications for moderate-to-severe plaque psoriasis and active psoriatic arthritis.

A steroid-free topical indicated for treatment of plaque psoriasis

Indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, and other assistance with breathing

Indicated for the improvement of glycemic control in patients with type 2 diabetes, in conjunction with diet and exercise

Indicated for acute treatment of agitation associated with schizophrenia or bipolar I or II disorder

A first-time generic for Vimpat, this drug treats partial onset seizures

Indicated for the treatment of mild-to-severe dementia of the Alzheimer’s type. This product is the first transdermal patch for this indication.

A first-time generic for Symbicort, this drug is indicated for the treatment of COPD and asthma.

A first-time generic for Farxiga, a medication used to treat type 2 diabetes, as well as adults with certain kinds of heart failure chronic kidney disease.

A first-time generic of Revex, this drug is indicated for the complete or partial reversal of opioid drug effects, including respiratory depressions from natural or synthetic opioids, and for the management of opioid overdose

Indicated for the treatment of chronic angina, a type of chest pain caused by reduced blood flow to the heart.

A peppermint-flavored solution indicated for the treatment of hypertension and angina. Amlodipine is available as a generic in oral tablets.

Indicated for the treatment of spasticity resulting from multiple sclerosis, as well as in patients with spinal cord injuries or diseases.

Indicated for the treatment of Hepatitis C genotypes 1-4 in patients without cirrhosis, or with compensated cirrhosis as part of a combination antiviral treatment regimen.

Indicated for the treatment of insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

Indicated to reduce the risk of HIV-1 infection

Indicated to improve glycemic control for type 1 and 2 diabetes

The 7th biosimilar approved for adalimumab. For the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s Disease, ulcerative colitis, and plaque psoriasis

Indicated for the treatment of seizures, and for the preventive treatment of migraine

Indicated for the treatment of opioid-induced constipation

Indicated for the emergency treatment of known or suspected opioid overdose

A combination opioid agonist and NSAID indicated for the management of acute pain severe enough to require an opioid and for which alternative treatments are inadequate

A biosimilar to Humira, this drug is now officially interchangeable with Humira for the treatment  of moderate-to-severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate-to-severe Crohn’s disease, moderate-to-severe ulcerative colitis, and moderate-to-severe chronic plaque psoriasis

Indicated for the treatment of major depressive disorder, obsessive compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, and PTSD

Indicated for the treatment of major depressive disorder (MDD)

Indicated for the acute treatment of migraine with or without aura

For the treatment of anxiety disorders in adults receiving stable, evenly divided, three times daily dosing with lorazepam tablets

A once-daily medication indicated to help lower blood sugar with type 2 diabetes, in conjunction with diet and exercise

Indicated for the acute treatment of migraine with or without aura

Indicated for the preventive treatment of episodic migraine

Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes

Adjunct treatment to diet and exercise to improve glycemic control in adults with type 2 diabetes

This is the first time a generic has been approved for Xeljanz XR – other formulations of Xeljanz have received generic approvals, but this new generic approval applies to the extended-release formulation. For the treatment of moderate-to-severe active rheumatoid arthritis, active psoriatic arthritis, or ulcerative colitis

This is the first time a generic has been approved for Duexis. For the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis, and to decrease the risk of developing upper gastrointestinal ulcers

This is the first time a generic has been approved for Belbuca. For the management of pain severe enough to require daily, around the clock, long-term opioid treatment for which alternative treatment options are inadequate

This is the first time a generic has been approved for Semglee. For the treatment of Type 1 and Type 2 diabetes, this drug is both a biosimilar to, and interchangeable with Lantus (insulin glargine)

For chronic weight management with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol) for use in addition to a reduced calorie diet and increased physical activity

A first-of-its-kind, biologic treatment for Alzheimer’s disease. This drug is the first new Alzheimer’s drug since 2003

This is the first time a generic has been approved for Xeljanz. For the treatment of moderate-to-severe active rheumatoid arthritis, and psoriatic arthritis

This is the first time a generic has been approved for Kaletra. For the treatment of HIV-1 infection

This is the first time a generic has been approved for Intelence. For the treatment of HIV-1 infection in treatment-experienced patients

This is the first time a generic has been approved for Perforomist. For the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema

This is the first time a generic has been approved for Brovana. For the long-term, twice daily administration in the maintenance of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema